Michel Meignan

7PUBLICATIONS
36CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical mycologyAnimal immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer

|Jan 06, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice

|Nov 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).

Emmanuel Bachy, Vincent Camus, Catherine Thieblemont

|Apr 28, 2021
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.

Stefan Alig, Charles W Macaulay, David M Kurtz

|Jul 14, 2018
FDG-PET in PMBCL: which heterogeneity?

Michel Meignan, Anne-Ségolène Cottereau

|Oct 14, 2017
PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.

A Gallamini, M Meignan

Pageof 2

Frequent Collaborators

4 joint publications

René-Olivier Casasnovas

2 joint publications

Aspasia Stamatoullas

2 joint publications

Andreas Hüttmann

2 joint publications

Franck Morschhauser